ProfileGDS5678 / 1425786_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 44% 42% 37% 25% 41% 42% 50% 42% 41% 42% 42% 49% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4339355
GSM967853U87-EV human glioblastoma xenograft - Control 23.0139944
GSM967854U87-EV human glioblastoma xenograft - Control 32.9668542
GSM967855U87-EV human glioblastoma xenograft - Control 42.7846437
GSM967856U87-EV human glioblastoma xenograft - Control 52.5389325
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0378241
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0353142
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1849850
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9444742
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.928141
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9546742
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9471142
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1614349
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9577842